Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | ENTPD5 | O75356 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10101178 | 0.94 | PIK3CB (0.42) | PIK3CBENTPD5CYP19A1TRPV1MAPKAPK2 | |
| SCHEMBL10101170 | 0.92 | PIK3CB (0.41) | PIK3CBENTPD5L3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL10101284 | 0.89 | PIK3CB (0.39) | PIK3CBENTPD5 | |
| SCHEMBL10101157 | 0.86 | PIK3CB (0.57) | PIK3CBENTPD5CYP19A1TRPV1MAPKAPK2 | |
| SCHEMBL10101285 | 0.85 | PIK3CB (0.43) | PIK3CBENTPD5CYP19A1L3MBTL3L3MBTL1 | |
| SCHEMBL10101133 | 0.82 | PIK3CB (0.47) | PIK3CBENTPD5CYP19A1TRPV1MAPKAPK2 | |
| SCHEMBL10101179 | 0.81 | PIK3CB (0.43) | PIK3CBENTPD5CYP19A1TRPV1MAPKAPK2 | |
| SCHEMBL10101390 | 0.80 | PIK3CB (0.41) | PIK3CBENTPD5CYP19A1TRPV1MAPKAPK2 | |
| SCHEMBL10101171 | 0.79 | PIK3CB (0.42) | PIK3CBENTPD5CYP19A1L3MBTL3L3MBTL1 | |
| SCHEMBL10101279 | 0.78 | PIK3CB (0.40) | PIK3CBENTPD5TRPV1MAPKAPK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101605-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS INC. (CA) | 2012-01-24 | — | — | US | disclosed |
| US-20110136802-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS INC. (CA) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136802-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPM1D, PTPRO, PPM1G | PIK3CB 98/4885ENTPD5 750/4885CYP19A1 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.